NCT06088290 2026-04-17
SaLuDo
PharmaMar
Phase 3 Recruiting
Clinical Trials
13 trialsNCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
NCT07328425 2026-04-03
ISG-TULIPS
Italian Sarcoma Group
Phase 2 Recruiting
NCT05918640 2026-03-31
LiFFT
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06228066 2026-03-23
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06681220 2026-03-11
Relapsed SCLC
VA Office of Research and Development
Phase 1/2 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT05734066 2026-02-03
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Jazz Pharmaceuticals
Phase 1/2 Recruiting
NCT05636111 2026-01-22
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05244239 2025-10-31
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Emory University
Phase 1 Recruiting
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting